| USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES |
USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES |
95%
|
USAspending awards from Department of Health and Human Services: $60,234,832 across 2 awards. 75A50118C00015 IGF::OT::IGF; 75N93021C00022 TO ADVANCE CLINICAL AND NON-CLINICAL DEVELOPMENT OF AN ANTIBI… |
| PFE |
Pfizer Inc. |
90%
|
In the third quarter of 2022, upon the completion of a milestone related to regulatory engagement for SPR206, Pfizer communicated its approval that the milestone was achieved, and the Company receive… |
| PFE |
Pfizer Inc. |
90%
|
Reciprocal relationship from PFE graph: Reciprocal relationship from SPRO graph: Reciprocal relationship from PFE graph: Reciprocal relationship from SPRO graph: Reciprocal relationship from PFE grap… |
| GLAXO-GROUP-LIMITED |
GLAXO-GROUP-LIMITED |
85%
|
contract inception, the total transaction price was $ 64.7 million, which included the initial payment of $ 66.0 million in the fourth quarter of 2022 and the discount of $ 1.3 million related to the… |
| GSK |
GSK plc |
85%
|
Reciprocal relationship from GSK graph: Reciprocal relationship from SPRO graph: contract inception, the total transaction price was $ 64.7 million, which included the initial payment of $ 66.0 milli… |
| VRTX |
Vertex Pharmaceuticals Incorporated |
72%
|
Reciprocal relationship from VRTX graph: Reciprocal relationship from SPRO graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from SPRO graph: Reciprocal relationship from VRTX g… |
| VRTX |
Vertex Pharmaceuticals Incorporated |
72%
|
were fully constrained as of December 31, 2024 and not included in the transaction price. The Company can also earn sales-based royalties. Pursuant to Amendment 2 to the GSK License Agreement, the Co… |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
ulting expenses incurred in the three months ended March 31, 2026. Facility-related and other costs primarily reflect costs related to supporting our general and administrative staff. Other Income (E… |
| CIPLA-THERAPEUTICS-INC |
CIPLA-THERAPEUTICS-INC |
62%
|
bject us to other risks. We may evaluate various acquisitions and strategic collaborations, including licensing or acquiring complementary products, intellectual property rights, technologies or busi… |
| CO-LTD |
CO-LTD |
62%
|
bject us to other risks. We may evaluate various acquisitions and strategic collaborations, including licensing or acquiring complementary products, intellectual property rights, technologies or busi… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
l property rights; • the potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign market (wit… |
| EVEREST-MEDICINES-II-LIMITED |
EVEREST-MEDICINES-II-LIMITED |
62%
|
n nature of these payments, the Company determined they were fully constrained as of March 31, 2026 and not included in the transaction price. The Company can also earn sales-based royalties. Pursuan… |
| NEW-PHARMA-LICENSE-HOLDINGS-LIMITED |
NEW-PHARMA-LICENSE-HOLDINGS-LIMITED |
62%
|
n nature of these payments, the Company determined they were fully constrained as of March 31, 2026 and not included in the transaction price. The Company can also earn sales-based royalties. Pursuan… |
| SPERO-POTENTIATOR-INC |
SPERO-POTENTIATOR-INC |
62%
|
n nature of these payments, the Company determined they were fully constrained as of March 31, 2026 and not included in the transaction price. The Company can also earn sales-based royalties. Pursuan… |
